Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review

Area of Science:

• Immunology
• Endocrinology
• Oncology

Background:

• Ipilimumab is a monoclonal antibody targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4).
• It enhances T-cell co-stimulation, promoting anti-tumour responses and is approved for metastatic melanoma.
• Immune-related adverse events are common due to immunostimulation.

Observation:

• Autoimmune endocrinopathies are frequent immune-related adverse events associated with ipilimumab.
• Autoimmune lymphocytic hypophysitis causing anterior panhypopituitarism has been reported in North America.
• A case of anterior panhypopituitarism developed after the third dose of ipilimumab in a male patient with metastatic melanoma.

Findings:

• The case presented demonstrates anterior panhypopituitarism following ipilimumab treatment.
• A review of the literature on ipilimumab-induced autoimmune lymphocytic hypophysitis is discussed.
• Management strategies for this condition are explored based on previous reports.

Implications:

• Recognition of ipilimumab-induced hypophysitis is crucial for timely management.
• Understanding the spectrum of immune-related adverse events is vital for oncologists.
• Further research into managing ipilimumab-associated toxicities can improve patient outcomes.